J Mol Med (2008) 86:1353–1365
DOI 10.1007/s00109-008-0397-0
ORIGINAL PAPER
Chromosomal changes characterize head and neck cancer
with poor prognosis
Verena L. Bauer & Herbert Braselmann &
Michael Henke & Dominik Mattern & Axel Walch &
Kristian Unger & Michael Baudis & Silke Lassmann &
Reinhard Huber & Johannes Wienberg &
Martin Werner & Horst F. Zitzelsberger
Received: 14 March 2008 / Revised: 8 July 2008 / Accepted: 23 July 2008 / Published online: 23 September 2008
# Springer-Verlag 2008
Abstract It is well established that genetic alterations may
be associated to prognosis in tumor patients. This study
investigates chromosomal changes that predict the clinical
outcome of head and neck squamous cell carcinoma
(HNSCC) and correlate to characteristic clinicopathological
parameters. We applied comparative genomic hybridization
(CGH) to tissue samples from 117 HNSCC patients
scheduled for radiotherapy. Genomic aberrations occurring
in more than five patients were studied for impact on
locoregional progression (LRP)-free survival. p values were
adjusted by the Hochberg–Benjamini procedure and significant aberrations and clinical variables subjected to a
stepwise backwards Cox proportional model. Significant
alterations were further analyzed by array-CGH and
fluorescence in situ hybridization (FISH). In multivariate
survival analysis gains on 1q and 16q predict reduced LRPfree survival independently from known prognostic factors.
Cluster analysis separated the HNSCC cases into two
groups (cluster 1 and 2) that are characterized by significant
differences for imbalances in 13 chromosomal regions.
Moreover, it became apparent that cluster 1 correlates to
nonanemic patients, while cluster 2 represents predominantly anemic cases. Array-CGH pinpoints 16q24.3 to be
the region of interest on chromosome 16 which was further
verified by FISH analysis where an increased copy number
of FANCA, a member of the Fanconi anemia/breast cancer
V. L. Bauer : H. Braselmann : K. Unger : R. Huber :
H. F. Zitzelsberger (*)
Institute of Molecular Radiation Biology,
Helmholtz Center Munich German Research Center for
Environmental Health GmbH,
Ingolstaedter Landstraße 1,
85764 Neuherberg, Germany
e-mail: zitzelsberger@helmholtz-muenchen.de
M. Baudis
Institute of Molecular Biology, University of Zurich,
Winterthurerstr. 190,
8057 Zurich, Switzerland
M. Henke
Clinic for Radiation Therapy, University Clinic Freiburg,
Robert-Koch-Strasse 3,
79106 Freiburg, Germany
J. Wienberg
Department Biology II, Anthropology and Human Genetics,
Ludwig-Maximilians University,
Grosshaderner Str. 2,
82152 Martinsried, Germany
D. Mattern : S. Lassmann : M. Werner
Institute of Pathology, University Clinic Freiburg,
Breisacherstrasse 115a,
79106 Freiburg, Germany
A. Walch
Institute of Pathology, Helmholtz Center Munich German
Research Center for Environmental Health GmbH,
Ingolstaedter Landstrasse 1,
85764 Neuherberg, Germany
K. Unger
Department of Histopathology, Imperial College London,
Hammersmith Hospital,
142 J Block, Du Cane Road,
W12 0NN London, UK
1354
J Mol Med (2008) 86:1353–1365
pathway, could be identified. This study demonstrates that
chromosomal gains on 1q and 16q as well as chromosomal
loss on 18q represent prognostic markers in HNSCC and
that these alterations may explain to some extent the dismal
course of a subgroup of patients.
malities. We could demonstrate an association of these two
tumor groups with the patients’ anemia status. Finally, we
were able to designate an amplified candidate gene as a
prognostic marker from array-CGH analysis.
Keywords HNSCC . Chromosomal imbalances .
Array-CGH . FA/BRCA pathway . Prognostic marker
Materials and methods
Patient data, treatment, and tumor tissues
Introduction
Head and neck squamous cell carcinoma (HNSCC)
represents the seventh most common cancer disease in the
US with approximately 47,000 new cases per year [1].
Clinical features predict the individual patients’ outcome,
such as location, extent of disease (including nodal
involvement), perilymphatic and perineural spread, and
extent of surgery [2–3]. Finally, anemia negatively affects
prognosis, independently from known prognostic factors
[4]. However, recent studies report decreased disease
control and survival in case of erythropoietin treatment for
anemia correction [5–8]. Besides these clinicopathologic
variables, malignant progression of HNSCC is characterized by the accumulation of genetic abnormalities [9–11]
and distinct genetic changes associated to a progressing and
recurrent disease [12, 13]. Frequent chromosomal imbalances in HNSCC have been reported on 3p, 4, 5q, 8p, 9p,
11, 13q, and 18q (losses) and 3q25–26, 5p, 8q24, 9q22–34,
11q13, 14q24, 16p, 19, 20q24, and 22q (gains) [14–15].
Several prognostic markers were identified in previous
studies including DNA gains on 3q21–29, 11q13, and
12q24 and losses on 5q11–15, 6q14–21, 8p21–22, 18q22,
and 21q11–21 [11, 16–18]. It has been suggested that gains
on 3q26 and 11q13 and deletions on 8p23 and 22q could be
valuable markers of aggressive disease [16, 19]. Also
chromosomal aberrations have been related to treatment
response; for example, loss of distal 11q has been
associated with DNA repair and reduced sensitivity to
ionizing radiation [20]. Although conventional comparative
genomic hybridization (CGH) studies revealed promising
prognostic markers, information about altered candidate
genes is limited due to the low resolution of CGH of about
10 Mb [21]. Therefore, advanced approaches like arrayCGH [22] may provide more detailed information on gene
alterations as prognostic factors. This is of particular
interest since pathways affected by genetic alterations can
be discovered and investigated.
In this study, we confirm previous findings and
furthermore identify new chromosomal markers in HNSCC
that correlate with poor clinical outcome. Additionally, we
show that HNSCC cases can be separated into two tumor
groups based on distinct patterns of chromosomal abnor-
In total, 117 tumor samples from HNSCC patients were
investigated. Sixty-eight tumor samples were derived from
anemic HNSCC patients participating in a multicenter trial
[5]. Inclusion criteria were anemia just before starting
radiotherapy (blood hemoglobin level according to common definitions for anemia: female—lower than 12 g/dL,
male—lower than 13 g/dL), age older than 18 years,
histologically proven squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx, or larynx, and scheduled
treatment with radiotherapy only or postoperative radiotherapy for advanced disease (T3, T4, or nodal involvement). A further eligibility criterion was a Karnofsky score
of 60 or more. Patients with any other simultaneous
malignant disease, treatment with any cytostatic drug,
pregnancy, or inadequate contraception were excluded.
Additionally, we selected 49 nonanemic patients with
HNSCC matched at the best for sex, location, stage,
resection, and treatment compliance. The study was
approved by the ethics committee of the Freiburg University Clinic and performed in accordance with the revised
Declaration of Helsinki.
Standard planning and radiation techniques were used
for both patient groups. The radiation volume included the
tumor (or tumor bed) with a 2–3-cm safety margin and the
regional lymph node areas. Six mega-electron-volt linear
accelerators were used and standard dose fractionation
protocols (five fractions of 2.0 Gy per week) were
followed. Sixty Gy (allowable range, 56 to 64 Gy) were
administered to regions for R0 or R1 resected disease and
70 Gy (allowable range, 66 to 74 Gy) for macroscopically
incompletely resected tumor (R2) or primary definitive
treatment. The spinal cord was shielded after 30–36 Gy.
Patients were seen for first follow-up 6 weeks after
completion of radiotherapy and, thereafter, every 3 months
to assess locoregional tumor control and survival. Detailed
patient data are summarized in Table 1.
Formalin-fixed and paraffin-embedded (FFPE) tissue
sections were stained with hematoxylin/eosin according to
standard procedures. The histopathological classification of
each sample was evaluated according to the guidelines of
the World Health Organization [23] and staging of tumors
was performed according to the criteria of the International
Union Against Cancer [24]. Microdissection was applied to
J Mol Med (2008) 86:1353–1365
1355
Table 1 Demography of
HNSCC patients
Number of patients
Females
Males
Current smoker
Nonsmoker
n.s.
Hemoglobin level
Nonanemic cases
Anemic cases
Radiotherapy
Recurrence of tumor after
radiotherapy
Tumor localization
Larynx
Hypopharynx
Oropharynx
Oral cavity
Staging
pT1
pT2
pT3
pT4
n.s.
pN0
pN1
pN2
pN3
Grading
G1
G2
G3
n.s.
Resection status
R0
R1
R2
Primary definitive
radiotherapy
Total
[%]
Alive without
disease
Alive with
tumor
Dead because
of tumor
Dead because
of other disease
117
13 [11.1]
104 [88.9]
56 [47,9]
46 [39,3]
15 [12,8]
47
8
39
20
17
10
7
1
6
3
4
–
29
3
26
13
14
2
34
1
33
20
11
3
49 [41,9]
68 [58,1]
114 [97,4]
24 [20,5]
28
19
47
–
–
7
7
4
4
25
27
20
17
17
33
–
12
32
44
29
[10,3]
[27,4]
[37,6]
[24,8]
4
15
17
11
1
1
3
2
4
8
9
8
3
8
15
8
14 [12]
35 [29,9]
23 [19,7]
42 [35,9]
3 [2,6]
16 [12,8]
29 [24,8]
68 [58,1]
4 [3,4]
8
15
11
11
2
5
12
29
1
–
4
1
2
–
1
2
3
1
2
7
7
13
–
5
7
16
1
4
9
4
16
1
5
8
20
1
3 [2,6]
62 [53]
44 [37,6]
8 [6,8]
1
24
21
1
–
3
3
1
1
21
6
1
1
14
14
5
40 [34,2]
13 [11,1]
4 [3,4]
60 [51,3]
28
6
1
12
2
1
–
4
5
3
2
19
5
3
1
25
n.s. Not specified
paraffin-embedded sections to enrich the tumor cell content
to more than 90%. Genomic DNA was extracted from
microdissected samples using a DNA extraction kit according to the manufacturer’s protocol (Qiagen, Hilden,
Germany).
Labeling of DNA
DNA extracted from paraffin-embedded tissues was indirectly
labeled by nick translation using biotin-16-dUTP for tumor
DNA and digoxigenin-11-dUTP for reference DNA which
was isolated from peripheral lymphocytes of a healthy male or
female donor. Nick translation of tumor and reference DNA
was performed according to standard protocols.
CGH and image analysis
For each CGH hybridization, 1 μg tumor DNA, 1 μg
reference DNA, 25 μg Cot-1 DNA (Invitrogen, Karlsruhe,
Germany), and 20 μg herring sperm DNA (Sigma-Aldrich,
Taufkirchen, Germany) were cohybridized to denatured
metaphases for 72 h at 37°C. After hybridization, biotinlabeled tumor DNA was detected with avidin-fluorescein
isothiocyanate (FITC) DCS (Vector Laboratories, Linaris,
Wertheim-Bettingen, Germany) and digoxigenin-labeled
reference DNA with anti-digoxigenin-rhodamine (Roche,
Mannheim, Germany). Slides were counterstained with
4′,6-diamidino-2-phenylindole (DAPI) and mounted in
antifade solution (Vectashield, Vector Laboratories). Images
1356
of at least ten metaphases were captured using a chargecoupled device camera (IMAC-CCD S30) and karyotyped
after visualization with a Zeiss Axioplan 2 fluorescence
microscope equipped with filter sets (single-band excitation
filters for DAPI, FITC, and tetramethylrhodamine isothiocyanate (TRITC)) and 63× (N.A. 1,25) and 100× (N.A. 1,4)
objectives (Plan-Neofluar, Zeiss). Averaged profiles were
generated by CGH analysis software (ISIS 3, V2.84;
MetaSystems, Altrussheim, Germany) from at least ten to
15 homologous chromosomes and interpreted according to
published criteria [25] using statistical probability limits
that adapt automatically to the real variability of the ratio
values. The system calculates intra-experiment standard
deviations (SDs) for all profile points in all chromosomes
and combines them with an empirically defined positionindependent inter-experiment standard deviation. From the
resulting total SD’s and the desired error probability, the
width of the confidence interval is determined using
Student t statistics. For the interpretation of the experiment,
the position-dependent confidence interval around the
normal value of 1 is plotted together with the averaged
tumor/reference ratio profile, side by side with the
chromosome ideogram. Chromosomal imbalances were
defined as gains and losses if the averaged tumor/reference
profile exceeds the position-dependent confidence interval.
A chromosomal gain was classified as high-level amplification when the CGH ratio exceeded a value of 1.5 or when
the FITC fluorescence showed a strong distinct signal by
visual inspection and the corresponding ratio profile was
diagnostic of overrepresentation.
Telomeric regions, heterochromatic regions, and the Y
chromosome show strong interindividual variations and were
therefore excluded from interpretation. Furthermore, deletions on 1p32-pter, 16p, 19, and 22 were eliminated from
evaluation due to a high rate of apparently abnormal ratios in
these regions in comparison of two normal DNAs [26].
Array-CGH
CGH of the entire genome identified six anemic patients
with a particular poor clinical outcome that related to gain
on 16q and did not depend on known prognostic factors.
Having sufficient DNA samples available from five of
these, we performed additional array-CGH analyses in
order to locate more precisely the chromosomal imbalances. One megabyte BAC array slides were kindly
provided by the Array Facility of the Wellcome Trust
Sanger Centre (Hinxton/Cambridge, UK). They contain
approximately 3,400 BAC clones spotted in duplicates
onto aminoreactive slides (CodeLink, GE Healthcare,
Buckinghamshire, England) and cover the whole human
genome in 1 Mb distances [27]. In one case, a 1.4 Mb BAC
array (HumArray 3.2) carrying 2,464 BAC clones from
J Mol Med (2008) 86:1353–1365
the UCSF Comprehensive Cancer Center (San Francisco,
CA, USA) was used.
DNA was checked for quality in array-CGH experiments
using a gene-specific multiplex polymerase chain reaction
(PCR) [28]. Female reference DNA of 450 ng (Promega,
Mannheim, Germany) and tumor DNA of 450 ng were
labeled with Cy3-dCTP and Cy5-dCTP (PerkinElmer,
Shelton, USA), respectively, using the BioPrime-Labelling
Kit (Invitrogen, Karlsruhe, Germany) overnight at 37°C.
One hundred thirty-five micrograms cot-1 DNA (Invitrogen), test, and reference DNAs were cohybridized using a
hybridization station (HS400, Tecan, Crailsheim, Germany)
for 23 h, washed, and dried. The slides were scanned
(GenePix Personal 4100A, Axon Laboratories, Molecular
Devices Corp, Chicago, IL, USA) and intensity ratios were
measured with an array-analysis software (GenePix Pro 6.0,
Axon Laboratories). Analysis was performed using the
web-based array-CGH evaluation platform CAPweb [29]
which is installed on a local via intranet accessible web
server. After import of raw data, the normalization
procedure which uses the R-package MANOR was performed using default parameters (exclusion of data points
with a replicate deviation of >0.1 and/or a foreground to
background signal ratio of <3). Segmentation of the dataset
using the R-package GLAD was performed using default
parameters with exception of the parameters GLAD.deltaN
(set to one time standard deviation of the dataset) and
GLAD.forceGL1/2 (set to 1.2 times SD of the dataset).
Data have been exported to the array data visualization tool
VAMP and analyzed for genomic copy number alterations.
Common regions of alterations of the analyzed cases have
been determined using the minimal alteration algorithm
which is implemented to the VAMP software. Regions
representing copy number alterations have been further
analyzed using the web-based database Ensembl (www.
ensembl.org) on the basis of National Center for Biotechnology Information build 36. For the array-CGH data, we
followed the Minimum Information About a Microarray
Gene Experiment guidelines and deposited them at the
public repository “ArrayExpress” from the European Bioinformatics Institute under the accession number E-TABM359.
FISH analysis using BAC clones
BAC clones from the 1 Mb BAC array mapping on
chromosome 16q within the amplified region (RP1121B21, RP11-354M24, RP11-533D19) were labeled with
biotin or digoxigenin by nick translation according to
standard protocols. Hybridization of BAC clones and of a
commercially available digoxigenin-labeled human chromosome 16 satellite probe (Chrombios, Raubling, Germany) to paraffin-embedded tissue sections of the six
J Mol Med (2008) 86:1353–1365
HNSCC cases carrying a DNA gain on 16q and detection
of fluorescent signals were performed as described previously [30].
Screening for human papillomavirus
Extracted DNA from 68 anemic tumors was screened for the
presence of human papillomavirus (HPV) of the high
(HPV16, HPV18), medium (HPV31, 33), and low (HPV6,
11) risk subtypes according to a published protocol [31] with
slight modifications: In brief, 2 μl of DNA were incubated
with 4 μl of 10 mM dNTPs, 5 μl PCR buffer containing
15 mM MgCl2, 1 μl of each forward and reverse primer
(GP5, GP6, at 20 pM), 0.5 μl Amplitaq Gold, and water
added up to a 50-μl reaction volume. The PCR was run with
95°C for 7 min, 40 cycles of 94°C/1 min, 40°C/45 s, 72°C/
45 s, and a final step of 72°C for 7 min. Subsequently, 10 μl
of the PCR product were run on a 2% agarose gel.
In parallel, a control PCR for β-globin was performed for
all 68 anemic DNA samples as described previously [32] and
yielded positive signals in 65/68 DNA samples. For the
DNA samples with acceptable β-globin-specific (65/68) and
a positive HPV-specific PCR signal (four out of 65), the
HPV-specific PCR products were purified (PCR Purification
Kit, Qiagen) and sequenced. For this, 1 μl of purified PCR
product was cycled with 3.2 μl of GP6 or GP5 primer (at
1 μM), 4 μl of 5× buffer, 4 μl of BigDye 1.0 reagent
(Appliedbiosystems), and water up to 20 μl, using a PCR
program with 96°C for 1 min and 24 cycles of 96°C/10 s,
50°C/5 s, and 60°C/4 min. This was followed by purification
of the cycle PCR products and their analysis on a capillary
sequencer (ABI310, Appliedbiosystems). Resulting sequences were confirmed by Basic Local Alignment Search Tool
(http://www.ncbi.nlm.nih.gov/BLAST) analysis.
Statistical analysis
The statistical analysis was carried out in three parts:
unsupervised cluster analysis of chromosomal changes,
correlation tests of chromosomal changes with clinicopathological parameters, and analysis of locoregional progression (LRP)-free survival. Unsupervised hierarchical cluster
analysis was done with R-package procedure hclust (www.
r-project.org), using default methods (Euclidian distance
and complete linkage). For cluster analysis, DNA copy
number changes were reduced to chromosome arm resolution in order to get more clear arrangements. Gains were
coded with 1, losses with −1, and normal regions with 0.
For each of the two major top branches of cluster analysis,
the frequency of chromosomal changes was compared and
characteristic alterations for both clusters were defined,
using cutoff values (total occurrence at least 20%, relation
between the two clusters at least 3:1 or vice versa).
1357
Potential associations of all chromosomal changes to
clinicopathological factors were examined with nonparametric tests such as Jonckheere–Terpstra trend test for
tumor size (pT) and nodal involvement (pN) and chi-square
test for histological grading, localization, resection status,
and anemia status [33].
LRP-free survival was analyzed for each chromosomal
region which was altered in at least six patients. LRP was
assumed when tumor size within the radiation volume
increased by more than 25% and time to LRP was defined
as the time between end of radiotherapy and locoregional
recurrence of the tumor or death whichever was detected
first. Patients were marked as censored if they were LRPfree and alive at the last follow-up. LRP-free survival
curves were calculated using the Kaplan–Meier method
[34]. The differences of the resulting two survival curves
between cases with and without a chromosomal alteration
were tested with the log-rank test [35]. Additionally, hazard
coefficients of chromosomal abnormalities, tumor size (pT),
nodal involvement (pN), histopathological grading, resection status, anemia status, and tumor localization were
calculated using a univariate Cox proportional hazards
regression model [36]. The survival-associated chromosomal alterations were also examined for pairwise coalterations on other chromosomal sites using Fisher’s exact
test. Statistical significance for chromosomal alterations in
the association tests for clinical parameters and in the
univariate log-rank survival test was determined according
to the Benjamini–Hochberg’s false discovery rate (FDR)
controlling procedure [37], allowing a FDR of q. If m is the
total number of significance tests, pi is the i-th smallest p
value and k is the largest i for which pi < = q × i/m, then all
smaller p values (pi < = pk) are indicating significance.
Finally, chromosomal abnormalities and clinicopathological
parameters were subjected together to one multivariate Cox
regression model together with a stepwise variable selection
procedure. Selected were only variables, chromosomal or
clinicopathological, proven to be statistically significant in
the univariate analyses.
Results
In total, 117 HNSCC patients were analyzed for chromosomal imbalances by CGH. The CGH results were
subjected to cluster analysis to detect tumor groups with
similar aberration patterns. This cluster analysis revealed
two separated tumor groups (Fig. 2) that correlate significantly with the anemia status of patients (22 anemic cases
in cluster 1, 46 anemic cases in cluster 2; p<0.0001).
Table 1 summarizes the demographic and outcome data.
A subgroup of 65 patients was additionally screened for
human papillomavirus subtype 16 to investigate the impact
1358
J Mol Med (2008) 86:1353–1365
of infection on patient’s survival. No statistical computation
was possible as the number of positive cases (four out of
65) was too low.
Correlation of outcome with CGH data
and clinicopathological parameters
The clinical parameters staging, resection status, and
anemia status showed a significant correlation to LRP
(Table 2). In addition, chromosomal abnormalities that
occurred in more than five patients were tested for a
correlation to LRP-free survival. DNA gains on 1q43 and
16q23–24 as well as DNA loss on 18q22 predict outcome
as visualized by Kaplan–Meier graphs (Fig. 1); this stays
significant even after Hochberg–Benjamini adjustment
(Table 3). Further, after multivariate survival analysis
resection and anemia status (hazard ratio 2.3 per stage, p<
0.0001 and hazard ratio 2.5, p=0.001, respectively) and
gains on 1q43 (hazard ratio 2.6, p=0.0076) and 16q23–24
(hazard ratio 6.0, p=0.0017) remain as independent contributions to LRP-free survival.
Chromosomal imbalances in tumor subgroups
Cluster analysis of CGH data revealed two different groups
of HNSCC. Cluster 1 consisted of 62 cases and cluster 2 of
55 cases (Fig. 2a). Minimal common regions of alterations
were identified in both subgroups (cluster 1:27 DNA gains,
16 high-level amplifications, 22 DNA losses; cluster 2:29
DNA gains, 28 high-level amplifications, 24 DNA losses).
DNA copy number changes and high-level amplifications
of both tumor groups are summarized in Table 4.
Both subgroups demonstrate a different pattern of
chromosomal changes (Fig. 2a), most striking differences
were observed for imbalances on chromosomes 1q32
(gain), 1q43 (gain), 3p13 (loss), 3p24 (loss), 4p16 (loss),
4q26 (gain), 7q22 (gain), 9p22 (loss), 11q13 (gain), 13q31
(loss), 16q23–24 (gain), 18q22 (loss), and 21q21 (loss;
Fig. 2b). Detailed CGH data from this study will be
accessible at www.progenetix.net along with publication of
this study. Loss of 16q23–24 was significantly associated
with resection status of tumors (5.3% in R0–2, 31.7% in
patients with primary definitive radiotherapy, FDR-adjusted
p=0.042). A similar association with the anemia status of
tumors was observed for chromosomal imbalances on
chromosomes 1p22–31, 1q22–23, 3q12–13, 4q12–13,
4q24–26, 5q21, 6q13–14, 6q22–24, 1q13, 12q21, 13q21–
31, and 19p/q (gains) and 3p13, 3p24, 4p15–16, 4q26–34,
9p22–24, 10p12–14, 11q23–24, 13q31–32, 16q12, 17p,
17q11–21, 18q12–23, 20q, and 21q21 (losses) with FDRadjusted p values<0.05. None of the tested chromosomal
changes were significantly associated with tumor localization, staging, lymph node metastasis, and grading (FDRadjusted p values>0.05).
Correlations within CGH data
It is of note that co-alterations on 1q43 and 16q23–24
occurred in five cases (p=0.0002). We also found coalterations of gain on 16q23–24 and loss on 3p14 in six
cases (p=0.0039).
Array-CGH analysis, FISH analysis, and identification
of candidate genes on 16q
BAC array analyses of tissues from five patients with gain on
16q verified the DNA gain on 16q24.3 in all cases. The BAC
clones RP11-21B21, RP11-354M24, and RP11-533D19
localize to this minimal region of chromosomal gain
(Fig. 3). Hybridization of these clones to paraffin-embedded
tissue sections, finally, confirmed this observation in individual samples (Fig. 3). Clone RP11-354M24 (FANCA gene
locus) showed amplified fluorescence in situ hybridization
(FISH) signals in 49.4% (case 14452/00), 57% (case 28731/
00), 70.6% (case 29783/99), 75.3% (case 44/00), 81.8%
(case 24419/98), and 85% (case 8826/01) of tumor cells
analyzed. Clones RP11-21B21 and RP11-533D19 demonstrated amplified FISH signals in 75.9% and 73.9% of cells,
respectively (case 29783/99). Interestingly, the highly variable FISH signal numbers per cell indicate a distinct genetic
heterogeneity within the tumor. Database analysis of these
three BAC clones (www.ensembl.org), finally, tagged genes
CDT1, CBFA2T3, RPL13, DPEP1, FANCA, MCR1, TUBB3,
and GAS8 to be most probably involved in the observed
DNA amplification.
Table 2 Significant hazard ratios for clinicopathological parameters determined by univariate regression with the Cox proportional hazards model
for locoregional progression-free survival
Parameter (levels)
Staging (pT0–pT3, pT4)
Resection status (R0, R1–2, primary definitive radiotherapy)
Nonanemic/anemic
Number of cases
per level
74/42
40/17/59
49/68
Hazard ratio
(per stage)
Log-rank test,
degrees of freedom (df)
p value
1.22
1.95 per stage
2.24
5.84, 1
19.9, 2
9.04
0.016
<0.0001
0.0026
J Mol Med (2008) 86:1353–1365
1359
Fig. 1 Impact of gains on chromosome 1q43 (a) and 16q23–24 (b) as well as loss on chromosome 18q22 (c) and of the patient’s anemic status
(d) on LRP-free survival in HNSCC patients. Ticks represent censored patients
Discussion
In this study, we describe distinct chromosomal changes of
tumor tissue from patients with HNSCC and prognostic
markers that predict patients’ outcome. We report for the
first time that chromosomal imbalances on 1q43, 16q23–
24, and 18q22 correlate significantly to LRP-free survival
in HNSCC. Further, frequent and recurrent DNA gains on
3q and 11q13 and deletions on 3p, 4p, 9p, and 11q confirm
previous reports [16, 19, 38–41]. Moreover, the pattern of
chromosomal alterations of this study compares well to
available data from the progenetix database ([42]; www.
progenetix.net). This demonstrates the reliability of our
CGH approaches used which have been performed at two
Table 3 Ten highest hazard ratios, determined by univariate regression with the Cox proportional hazards model for comparison of locoregional
progression-free survival in patients with and without chromosomal imbalances
Chromosomal region
Abnormality
16q23–24
1q43
18q22
1p36.2
20p11.2
1p21
5p15.3
10p14
15q15
9p24
Gain
Gain
Loss
Gain
Loss
Gain
Gain
Loss
Gain
Loss
a
b
Hazard ratio
Log-rank statistic
Unadjusted p value
Adjusted p valuea
8.43
2.71
2.32
2.24
2.20
2.01
1.94
1.94
1.90
1.83
31.1
11.59
11.64
3.68
2.41
3.17
3.21
3.17
2.30
3.87
<0.0001
0.0007
0.0006
0.055
0.12
0.075
0.073
0.075
0.13
0.049
0.0004b
0.048b
0.048b
0.74
0.74
0.74
0.74
0.74
0.74
0.74
According to Benjamini–Hochberg’s FDR controlling procedure
Significant (FDR<0.05)
1360
Fig. 2 Dendrogram of hierarchical cluster analysis based on complete
linkage and Euclidian distance. Colored bars indicate tumors from
anemic (light blue) and nonanemic (dark blue) patients. DNA gains
J Mol Med (2008) 86:1353–1365
(green) and losses (red) are arranged by tumor groups. High-level
amplifications are indicated in white (a). Significant differences in the
aberration pattern between both groups became apparent (b)
J Mol Med (2008) 86:1353–1365
1361
Table 4 Minimal common regions of chromosomal imbalances and high-level amplifications
DNA—gains
Chromosomal region
Cluster 1 (62 cases)
1p22–31
1q31
1q44
2p15–16
2q31–33
2q32–33
3q13.1–13.2
3q25–27
3q25–26.3
4q13
4q26
4q28–31.2
5p13
5p13–14
5q21
6q13–14
6q22–23
7p14–22
7p13-pter
7q21
7q21–22
8q21.1–23
8q12–24.3
9p22–24
9p21–24
9q21–34
9q21–34
10q21
10q22
11q13
11q13
12p
12q21
13q21
14q21
15q14–25
18p
18q11.2–12
18q11.2–21
19p
19q
20p
20q12
Cluster 2 (55 cases)
1p34.3–36.2
1p34.2–36.1
1q31–32
1q32–44
2p15–22
2p14–16
2q32
2q24–32
3q26.1-qter
DNA—losses
Frequency (%)
Tumor site
Chromosomal region
Frequency (%)
Tumor site
16.4
14.8
8.2
8.2
26.2
1.6
52.5
21.0
59.0
31.1
36.1
1.6
16.4
3.2
29.5
31.1
24.6
9.8
1.6
14.8
4.8
31.1
1.6
13.1
1.6
4.9
1.6
6.6
3.2
11.5
4.8
1.6
27.9
19.7
9.8
1.6
1.6
6.6
3.2
11.5
9.8
1.6
6.6
HP/L/OC/OP
HP/OC/OP
HP/OC/OP
HP/OP
HP/L/OC/OP
HP
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
HP/OC/OP
HP
HP/OC/OP
OC/OP
HP/OC/OP
HP/L/OC/OP
HP/OC/OP
HP/OC/OP
OC
HP/OC/OP
HP/OP
HP/OC/OP
OP
HP/OC/OP
OC
HP/OC/OP
OP
HP/OP
OP
HP/L/OC/OP
HP/OC/OP
HP
HP/OC/OP
HP/OC/OP
HP/OP
OP
OC
HP/OC/OP
OC/OP
HP/L/OC/OP
HP/OC/OP
HP
HP/OC
2q12–21
3p14–21
8.2
21.3
HP/L/OC/OP
HP/L/OC/OP
7q36
8p22
11.5
26.2
HP/OC/OP
HP/L/OC/OP
9p13
21.3
HP/L/OC/OP
9q34
10p13–14
18.0
4.9
HP/OC/OP
OC/OP
10q25
14.8
HP/OC/OP
11p15
11q1
11q23
12q24.1–24.2
9.8
9.8
26.2
18.0
HP/OC/OP
HP/OC/O
HP/OC/OP
HP/L/OC/OP
13q31–33
9.8
HP/L/OC/OP
14q32
8.2
OC/OP
16.1
10.9
39.3
10.9
17.9
5.5
37.5
7.3
59.6
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
L/OC/OP
HP/L/OC/OP
OP
HP/L/OC/OP
HP/L
HP/L/OC/OP
15q13
15q23–24
16q23
11.5
18.0
31.1
HP/L/OC/OP
HP/L/OP
HP/L/OC/OP
17p12
24.6
HP/OC/OP
17q12–21
19.7
HP/OC/OP
18q21–22
20q12–13.2
21q21–22
11.5
27.9
8.2
HP/OC/OP
HP/L/OC/OP
HP/OC/OP
1p22–31
16.1
HP/L/OC/OP
2p23–25
10.7
HP/L/OP
2q13–22
2q36–37
3p24
3p13–14
4p15.3–16
10.7
21.4
57.1
60.7
62.5
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
1362
J Mol Med (2008) 86:1353–1365
Table 4 (continued)
DNA—gains
DNA—losses
Chromosomal region
Frequency (%)
Tumor site
3q24–29
4q24–26
4q12–22
5p14–15.1
5p
6p21.3
6p12–21.1
6q22–24
6q22–23
7p12–15
7q21–22
7q11.2–31
8q21.3–24.1
8q22–24.2
9p
9q22-qter
9q22–31
10p
10p
11q13
11q13
12p11.2
12p
12q13
12q13–21
13q14–22
13q12–21
14q22
14q11.2–13
15q21–22
15q
16p
16q22-qter
16q
17p12–13
17p
Cluster 2 (55 cases)
17q11.2–21
17q25
17q23–25
18p11.3
19p13.3
19q
19q
20p
20q12–13.2
20q
22q13
22q12–13
23.6
7.1
1.8
17.9
3.6
33.9
7.3
10.7
1.8
17.9
37.5
10.9
35.7
10.9
1.8
16.1
7.3
8.9
3.6
53.6
30.9
30.4
5.5
33.9
9.1
10.7
1.8
30.4
7.4
26.8
3.6
3.6
8.9
3.6
10.7
5.5
HP/L/OC/OP
HP/OC
OP
HP/L/OC/OP
L
HP/L/OC/OP
HP/L/OP
HP/L/OC/OP
L
HP/L/OC/OP
HP/L/OC/OP
HP/L
HP/L/OC/OP
HP/L/OC/OP
OP
HP/OC/OP
HP/OC/OP
HP/L/OC/OP
OC/OP
HP/L/OC/OP
HP/L/OC/OP
HP/OC/OP
HP/OC
HP/L/OC/OP
HP/OC
HP/OC/OP
HP
HP/L/OC/OP
HP/L/OC/OP
HP/L/OC/OP
L/OC
OC/OP
HP/L/OC/OP
L/OP
HP/L/OC/OP
OC/OP
26.8
23.2
7.3
21.4
30.4
23.2
1.8
1.8
23.2
1.8
19.6
3.6
HP/L/OC/OP
HP/L/OC/OP
OC/OP
HP/OC/OP
HP/L/OC/OP
HP/L/OC/OP
OP
L
HP/L/OC/OP
OP
HP/L/OC/OP
OC/OP
Bold—high-level amplifications
OC Oral cavity, OP oropharynx, L larynx, HP hypopharynx
Chromosomal region
4q32–34
5p14–15.1
Frequency (%)
26.8
8.9
Tumor site
HP/L/OC/OP
HP/OC/OP
5q32–34
33.9
HP/L/OC/OP
7q33–36
14.3
HP/L/OC/OP
8p22
9p13–21
51.8
53.6
HP/L/OC/OP
HP/L/OC/OP
9q21
14.3
HP/L/OC/OP
10p12–13
10q25–26
17.9
28.6
HP/L/OC/OP
HP/OC/OP
11p14–15
23.2
HP/L/OC/OP
11q23–24
55.4
HP/L/OC/OP
12q24.2–24.3
7.1
HP/OC/OP
13q31–32
33.9
HP/L/OC/OP
16q22–23
19.6
HP/OC/OP
17p12–13
5.4
HP/OC/OP
18q22
48.2
HP/L/OC/OP
21q21
33.9
HP/L/OC/OP
J Mol Med (2008) 86:1353–1365
1363
Fig. 3 Array-CGH and FISH on 16q23–24. a Array-CGH profiles
displaying a minimal amplified region on 16q24.3 (red bar); dots—
log2-ratios of BAC clones indicating no alteration (black), deletion
(red), DNA gain (green). FANCA FISH analysis with clone RP11-
354M24 (red signals, arrows if amplified) and chromosome 16
centromeric region (signals in green) for anemic HNSCC cases
29783/99 (b), 28731/00 (c), 14452/00 (d), 44/00 (e), 8826/01 (f),
24419/98 (g)
different resolution levels (5 to 10 Mb for conventional
CGH and approximately 1 Mb for array-CGH on selected
cases). We also validated exemplary array-CGH findings by
FISH on FFPE sections.
It is noteworthy that two subgroups of HNSCC could be
identified from our CGH data by cluster analysis. Charac-
teristic changes can be attributed to each tumor group
which suggests that different routes of tumor progression
exist. Interestingly, these two tumor groups also correlate
with the anemia status of patients indicating a specific
aberration pattern, if anemia has developed. This observation of distinct genetic changes in anemic HNSCC patients
1364
suggests that particular chromosomal aberration patterns
favor a more malignant phenotype. Thus, we can imagine
anemia to bring about tissue hypoxia that, on the other
hand, may promote progressing genetic changes and select
a more malignant and treatment resistant progeny [43]. This
interpretation is also supported by the highly significant
association between LRP-free survival and the anemic
status of patients (Table 2).
Among the above mentioned prognostic markers, we
considered the DNA gain on 16q23–24 as most relevant
because (1) it shows the most significant effect on survival
(Table 2), (2) it could be confirmed in multivariate testing,
and (3) it appeared as a co-alteration with 1q43 gain (a
second prognostic marker in this study) and 3p14 loss (a
common alteration in squamous cell cancers) suggesting a
strong impact in tumor development. For these reasons, we
decided to investigate the 16q23–24 gain further for the
involvement of particular candidate genes.
It became obvious from the array-based analyses that
16q24.3 harbors FANCA, a key regulator of the Fanconi
anemia (FA)/breast cancer (BRCA) pathway controlling
homology-directed DNA repair [44]. FANCA cooperates
with FANCC, FANCE, FANCF, FANCG, and BRCA1 and
BRCA2, RAD51, and the MRE11/RAD50/NBS1 complex.
Large deletions on 3p, 9q, 11q, and 13q, respectively,
suggest FANCD2, FANCC, MRE11, BRCA2/FANCD1 to
be additionally involved (Table 4). Furthermore, array-CGH
analysis revealed amplified regions on 5q and 17q (data not
shown) mapping for candidate genes RAD50 and BRCA1
which are also part of the FA/BRCA pathway. To validate
the significance of changes along the FA/BRCA pathway in
HNSCC, more detailed analyses at mRNA and protein
expression level are essential. The reported findings from
this study were obtained from a small subunit of tumors.
Therefore, a larger number of cases must be investigated for
confirmation of these changes which require a FA/BRCA
pathway-specific array or an appropriate multiplex ligationdependent probe amplification PCR approach.
The other prognostic markers of poor survival, gain on
1q43 and loss on 18q22, also harbor tumor-related
candidate genes that might affect the malignancy of tumor
cells. There are several genes located on 18q22 (cadherin 7,
cadherin 19, and DNAM-1 (CD226)) which mediate cell–
cell adhesion and thus could influence tumor invasion and
metastasis [45, 46]. Also the suppressor of cytokine
signaling (SOCS6) is affected by the deletion which
presumably influences the Janus kinase/signal transducers
and activators of transcription cascade and thus regulation
processes of signal transduction and cell growth [47]. The
amplified region on 1q43 contains galectin 8 which is
implicated in processes such as development, differentiation, cell–cell adhesion, and growth regulation [48]. Within
the same region also exonuclease 1 and MTR-5 are located,
J Mol Med (2008) 86:1353–1365
which are both implicated with increased risk for colon
cancer and HNSCC, respectively [49, 50].
In conclusion, chromosomal imbalances discriminate
subgroups of HNSCC that correlate to the anemic status of
patients. Chromosomal gains on 1q and 16q as well as loss
on 18q confer to some extent to the particular poor prognosis
of these patients. It is likely that anemia promotes malignant
progression by the accumulation of genetic changes and the
selection of a treatment-resistant phenotype.
Acknowledgements The skilful technical assistance of E. Konhäuser
and Anja Schöpflin is gratefully acknowledged. We would like to
acknowledge Cordelia Langford and the Wellcome Trust Sanger
Institute microarray facility for providing the 1-Mb BAC arrays.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ
(2008) Cancer Statistics, 2008. CA Cancer J Clin 58:71–96
2. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK,
Laramore GE, Al-Sarraf M (1998) Precisely defining high-risk
operable head and neck tumors based on RTOG #85-03 and #8824: targets for postoperative radiochemotherapy? Head Neck
20:588–594
3. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA
(1982) Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci 7:185–192
4. Frommhold H, Guttenberger R, Henke M (1998) The impact of
blood hemoglobin content on the outcome of radiotherapy. The
Freiburg experience. Strahlenther Onkol 4:31–34
5. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B,
Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003)
Erythropoietin to treat head and neck cancer patients with anaemia
undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet 362:1255–1260
6. Leyland-Jones B, Semiglazov V, Pawlicki M, Pawlicki M,
Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A,
Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X,
Vercammen E (2005) Maintaining normal hemoglobin levels with
epoetin alfa in mainly nonanemic patients with metastatic breast
cancer receiving first-line chemotherapy: a survival study. J Clin
Oncol 23:5960–5972
7. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C,
Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B,
Okawara GS, Levine MN (2007) Randomized, double-blind,
placebo-controlled trial of erythropoietin in non-small-cell lung
cancer with disease-related anemia. J Clin Oncol 25:1027–1032
8. Henke M, Laszig R, Frommhold H (2004) Erythropoietin to treat
anaemia in patients with head and neck cancer. Lancet 363:81–82
9. Sidransky D (1995) Molecular genetics of head and neck cancer.
Curr Opin Oncol 7:229–233
10. Estilo CL, O-Charoenrat P, Ngai I, Patel SG, Reddy PG, Dao S,
Shaha AR, Kraus DH, Boyle JO, Wong RJ, Pfister DG, Huryn
JM, Zlotolow IM, Shah JP, Singh B (2003) The role of novel
oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma
of the oral tongue. Clin Cancer Res 9:2300–2306
11. Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D,
Shaha AR, Shah JP, Rao PH, Singh B (2004) Identification of novel
prognosticators of outcome in squamous cell carcinoma of the head
and neck. J Clin Oncol 22:3965–3972
J Mol Med (2008) 86:1353–1365
12. Partridge M, Emilion G, Falworth M, A’Hern R, Phillips E,
Pateromichelakis S, Langdon J (1999) Patient-specific mutation
databases for oral cancer. Int J Cancer 84:284–292
13. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K,
Epstein JB, Priddy R, Le ND, Zhang L (2000) Use of allelic loss to
predict malignant risk for low-grade oral epithelial dysplasia
[comment]. Clin Cancer Res 6:357–362
14. Bockmühl U, Schwendel A, Dietel M, Petersen I (1996) Distinct
patterns of chromosomal alterations in high- and low-grade head
and neck squamous cell carcinomas. Cancer Res 56:5325–5329
15. Singh B, Gogineni SK, Sacks PG, Shaha AR, Shah JP, Stoffel A,
Rao PH (2001) Molecular cytogenetic characterization of head
and neck squamous cell carcinoma and refinement of 3q
amplification. Cancer Res 61:4506–4513
16. Bockmühl U, Schlüns K, Küchler I, Petersen S, Petersen I (2000)
Genetic imbalances with impact on survival in head and neck
cancer patients. Am J Pathol 57:369–375
17. Bockmühl U, Ishwad CS, Ferrell RE, Gollin SM (2001)
Association of 8p23 deletions with poor survival in head and
neck cancer. Otolaryngol Head Neck Surg 124:451–455
18. Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX,
Rybicki BA, Dyke DL (1998) Loss of 18q predicts poor survival
of patients with squamous cell carcinoma of the head and neck.
Genes Chromosomes Cancer 21:333–339
19. Ashman JN, Patmore HS, Condon LT, Cawkwell L, Stafford ND,
Greenman J (2003) Prognostic value of genomic alterations in
head and neck squamous cell carcinoma detected by comparative
genomic hybridization. Br J Cancer 89:864–869
20. Parikh RA, White JS, Huang X, Schoppy DW, Baysal BE,
Baskaran R, Bakkenist CJ, Saunders WS, Hsu L, Romkes M,
Gollin SM (2007) Loss of distal 11q is associated with DNArepair deficiency and reduced sensitivity to ionizing radiation in
head and neck squamous cell carcinoma. Genes Chromosomes
Cancer 46:761–775
21. Snijders AM, Pinkel D, Albertson DG (2003) Current status and
future prospects of array-based comparative genomic hybridisation. Brief Funct Genomic Proteomic 2:37–45
22. Pinkel D, Albertson DG (2005) Comparative genomic hybridization. Annu Rev Genomics Hum Genet 6:331–335
23. Barnes L, Everson JW, Reichart P, Sidransky D (eds) (2005)
World health organisation classification of tumours: pathology and
genetics of head and neck tumours. IARC, Lyon
24. Sobin LH, Wittekind Ch (eds) (2002) UICC: TNM classification
of malignant tumours, 6th ed. Wiley-Liss, New York
25. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW,
Waldman F, Pinkel D (1992) Comparative genomic hybridization
for molecular cytogenetic analysis of solid tumors. Science
258:818–821
26. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM,
Gray JW, Pinkel D (1994) Optimizing comparative genomic
hybridization for analysis of DNA sequence copy number changes
in solid tumors. Genes Chromosomes Cancer 10:231–243
27. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE,
Smith J, Vetrie D, Gorman P, Tomlinson IP, Carter NP (2003)
DNA microarrays for comparative genomic hybridization based
on DOP-PCR amplification of BAC and PAC clones. Genes
Chromosomes Cancer 36:361–374
28. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB,
Verhoef S, Nederlof PM (2006) A multiplex PCR predictor for a
CGH success of FFPE samples. Br J Cancer 94:333–337
29. Hupé P, Stransky N, Thiery JP, Radvanyi F, Barillot F (2004)
Analysis of array-CGH data: from signal ratio to gain and loss of
DNA regions. Bioinformatics 20:3413–3422
30. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T,
Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P,
Thomas G (2004) Heterogeneity in the distribution of RET/PTC
1365
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
rearrangements within individual post-Chernobyl papillary thyroid
carcinomas. J Clin Endocrin Metab 89:4272–4279
Merkelbach-Bruse S, Jakob C, Tietze L, Schroder W, Rath W,
Fuzesi L (1999) Consensus polymerase chain reaction and
enzyme-linked immunosorbent assay for human papillomavirus
detection and typing in cervical specimens. Diagn Mol Pathol
8:32–38
Lassmann S, Gerlach UV, Technau-Ihling K, Werner M, Fisch P
(2005) Application of BIOMED-2 primers in fixed and decalcified
bone marrow biopsies: analysis of immunoglobulin H receptor
rearrangements in B-cell non-Hodgkin’s lymphomas. J Mol Diagn
7:582–591
Lehmann EL (1975) Nonparametrics, statistical methods based on
ranks. McGraw Hill Higher Education, New York
Kaplan E, Meier P (1958) Nonparametric estimation from
incomplete observations. J Am Stat Assoc 53:457–481
Kalbfleisch JD, Prentice RL (1980) The statistical analysis of
failure time data. Wiley series in probability and statistics. Wiley,
New York
Cox D (1972) Regression models and life tables (with discussion).
J R Stat Soc B 34:187–220
Benjamini Y, Hochberg Y (1995) Controlling the false discovery
rate: a practical and powerful approach to multiple testing. J R
Stat Soc B 57:289–300
Speicher MR, Howe C, Crotty P, du Manoir S, Costa J, Ward DC
(1995) Comparative genomic hybridization detects novel deletions and amplifications in head and neck squamous cell
carcinomas. Cancer Res 55:1010–1013
Bockmühl U, Wolf G, Schmidt S, Schwendel A, Jahnke V, Dietel M,
Petersen I (1998) Genomic alterations associated with malignancy in
head and neck cancer. Head Neck 20:145–151
Gollin SM (2001) Chromosomal alterations in squamous cell
carcinomas of the head and neck: window to the biology of
disease. Head Neck 23:238–253
Struski S, Doco-Fenzy M, Cornillet-Lefebvre P (2002) Compilation of published comparative genomic hybridization studies.
Cancer Genet Cytogenet 135:63–90
Baudis M, Cleary ML (2001) Progenetix.net: an online repository for
molecular cytogenetic aberration data. Bioinformatics 17:1228–1229
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe
SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with
diminished apoptotic potential in solid tumours. Nature 379:88–91
D’Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA
pathway. Nat Rev Cancer 3:23–24
Blons H, Laccourreye O, Houllier AM, Carnot F, Brasnu D, Beaune
P, Zucman-Rossi J, Laurent-Puig P (2002) Delineation and candidate
gene mutation screening of the 18q22 minimal region of deletion in
head and neck squamous cell carcinoma. Oncogene 21:5016–5023
Hajra KM, Fearon ER (2002) Cadherin and catenin alterations in
human cancer. Genes Chromosomes Cancer 34:255–268
Storojeva I, Boulay JL, Ballabeni P, Buess M, Terracciano L,
Laffer U, Mild G, Herrmann R, Rochlitz C (2005) Prognostic and
predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on
chromosome 18q in colorectal cancer. Oncology 68:246–255
Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E,
Geider B, Zick Y (2001) Galectin-8 functions as a matricellular
modulator of cell adhesion. J Biol Chem 276:31285–31295
Wu Y, Berends MJ, Post JG, Mensink RG, Verlind E, Van der Sluis T,
Kempinga C, Sijmons RH, van der Zee AG, Hollema H, Kleibeuker
JH, Buys CH, Hofstra RM (2001) Germline mutations of EXO1 gene
in patients with hereditary nonpolyposis colorectal cancer (HNPCC)
and atypical HNPCC forms. Gastroenterol 120:1580–1587
Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K,
Saito T, Sato S, Ueda R, Tajima K (2007) One-carbon metabolismrelated gene polymorphisms and risk of head and neck squamous
cell carcinoma: case-control study. Cancer Sci 98:1439–1446